The non-invasive fecal occult blood test is used as a effective tool to screen for bleeding without symptoms in the lower gastrointestinal tract.

In Taiwan, colorectal cancer is increasing, and ulcers and other upper GI tract issues are common. Same-day upper GI tract endoscopies and colonoscopies are commonly used to screen for cancer.
Of the total participants in the study, 397 people (14.2%) had a positive iFOBT result, indicating bleeding. The iFOBT was specific for almost 90% of colorectal cancers, adenomas and important lower GI lesions. Lower GI lesions were more common (24.1%) compared with those in the upper GI tract (17.9%). Lesions in the lower GI tract were more frequent in iFOBT-positive screens than in negative screens (41.3% versus 21.3%), whereas the frequency of lesions in the upper GI tract was similar in both positive and negative screens.
"Among participants found to have a malignant lesion, almost all who had colon cancer had a positive fecal test result (27/28, 96.4%). In contrast, none of the three participants found to have esophageal or gastric cancer had a positive fecal test result," writes Ming-Shiang Wu, Department of Internal Medicine, National Taiwan University, Taiwan, with coauthors.
"We found that the specificity of the immunochemical fecal occult blood test was almost 90% for predicting colorectal cancer, adenoma or any important lesion in the lower gastrointestinal tract. These findings support those of previous studies showing that the immunochemical fecal test is a specific diagnostic tool,"" write the authors.
Source-Eurekalert
MEDINDIA




Email









